Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
POMALYST (Celgene Pty Ltd)
Product name
POMALYST
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
175 working days (255)
Active ingredients
pomalidomide
Registration type
EOI
Indication
POMALYST (capsules), in combination with bortezomib and dexamethasone, is now also indicated for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior treatment regimen including lenalidomide.